



IAP15 Rec'd PCT/PTO 30 MAY 2006
PG

CASE ON/4-32721A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
<u>EV 72727402045</u> Express Mail Label Number	<u>MAY 30, 2006</u> Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
HOUGHTON ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/11271

FILED: 10 OCTOBER 2003

U.S. APPLICATION NO: 10/530,618

35 USC §371 DATE: 23 FEBRUARY 2006

FOR: USE OF IMATINIB (GLIVEC, STI-571) TO INHIBIT BREAST
CANCER RESISTANCE PROTEIN (BCRP)-MEDIATED
RESISTANCE TO THERAPEUTIC AGENTS

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed April 7, 2005. Since Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, no fees are believed to be required under 37 C.F.R. §1.97(b)(3). If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7852




Oona A. Jackson
Attorney for Applicants
Reg. No. 48,152

Date: 5/30/06

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
ON/4-32721A
APPLICATION NO.
10/530,618
APPLICANT
HOUGHTON ET AL.
FILING DATE
FEBRUARY 23, 2006

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Houghton et al., "Imatinib mesylate (STI571, Gleevec) is a potent inhibitor of BCRP (ABCG2) and reverses topotecan resistance in vitro," Abstract No. 1959, Proceedings of the American Association for Cancer Research, Vol. 44, March (2003) Abstract
	AS	Litman et al., "From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance," Cellular and Molecular Life Sciences, Vol. 58, pp. 931-959 (2001)
	AT	Lage et al., "Effect of the breast-cancer resistance protein on atypical multidrug resistance," The Lancet Oncology, Vol. 1, pp. 169-75 (2000)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
ON/4-32721A
APPLICATION NO.
10/530,618
APPLICANT
HOUGHTON ET AL.
FILING DATE
FEBRUARY 23, 2006

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	Ross D.D., "Novel mechanisms of drug resistance in leukemia," Leukemia, Vol. 14, pp. 467-473 (2000)
	DB	Wu et al., "Drug-resistant proteins in breast cancer: recent progress in multidrug resistance," Ai Zheng, Vol. 22(4), pp. 441-4 (2003) Abstract
	DC	Tan et al., "Multidrug resistance transporters and modulation," Current Opinion in Oncology 2000, Vol. 12, pp. 450-458 (2000)
	DD	Kawabata et al., "Breast Cancer Resistance Protein Directly Confers SN-38 Resistance of Lung Cancer Cells," Biochemical and Biophysical Research Communications, Vol. 280, pp. 1216-1223 (2001)
	DE	Erllichman et al., "The HER Tyrosine Kinase Inhibitor CI1033 Enhances Cytotoxicity of 7-Ethyl-10-hydroxycamptothecin and Topotecan by Inhibiting Breast Cancer Resistance Protein-mediated Drug Efflux," Cancer Research, Vol. 61, pp. 739-748 (2001)
	DF	Sparreboom et al., "Pharmacogenomics of ABC transporters and its role in cancer chemotherapy," Drug Resistance Updates 6, pp. 71-84 (2003)
	DG	
	DH	
	DI	
	DJ	
	DK	
	DL	
	DM	
	DN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.